PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic kras

Science Signaling

Volumn 6, Issue 304, 2013, Pages

  Diaz Flores, Ernesto ^a   Goldschmidt, Hana ^a   Depeille, Philippe ^b   Ng, Victor ^a   Akutagawa, Jon ^a   Krisman, Kimberly ^a   Crone, Michael ^a   Burgess, Michael R ^c   Williams, Olusegun ^c   Houseman, Benjamin ^c   Shokat, Kevan ^c   Sampath, Deepak ^d   Bollag, Gideon ^e   Roose, Jeroen P ^b   Braun, Benjamin S ^a   Shannon, Kevin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENENTECH INC   (United States)

^e PLEXXIKON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; DIACYLGLYCEROL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SECOND MESSENGER; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; CELLS, CULTURED; CYTOKINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEMATOPOIETIC STEM CELLS; LEUKEMIA; MAP KINASE SIGNALING SYSTEM; MICE; MUTATION, MISSENSE; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOLIPASE C GAMMA; PROTO-ONCOGENE PROTEINS P21(RAS); SECOND MESSENGER SYSTEMS; TOR SERINE-THREONINE KINASES;

EID: 84889258773     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004125     Document Type: Article

References (61)

1. S. Donovan, K. M. Shannon, G. Bollag, GTPase activating proteins: Critical regulators of intracellular signaling. Biochim. Biophys. Acta 1602, 23-45 (2002).
2. I. R. Vetter, A. Wittinghofer, The guanine nucleotide-binding switch in three dimensions. Science 294, 1299-1304 (2001).
3. J. L. Bos, H. Rehmann, A. Wittinghofer, GEFs and GAPs: Critical elements in the control of small G proteins. Cell 129, 865-877 (2007).
4. J. Downward, Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11-22 (2003).
5. T. Maurer, L. S. Garrenton, A. Oh, K. Pitts, D. J. Anderson, N. J. Skelton, B. P. Fauber, B. Pan, S. Malek, D. Stokoe, M. J. Ludlam, K. K. Bowman, J. Wu, A. M. Giannetti, M. A. Starovasnik, I. Mellman, P. K. Jackson, J. Rudolph, W. Wang, G. Fang, Smallmolecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. U.S.A. 109, 5299-5304 (2012).
6. A. M.Wahlstrom, B. A. Cutts, M. Liu, A. Lindskog, C. Karlsson, A. K. Sjogren, K. M. Andersson, S. G. Young, M. O. Bergo, Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 112, 1357-1365 (2008).
7. J. Xu, C. Hedberg, F. J. Dekker, Q. Li, K. M. Haigis, E. Hwang, H.Waldmann, K. Shannon, Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. Blood 119, 1032-1035 (2012).
8. J. O. Lauchle, B. S. Braun, M. L. Loh, K. Shannon, Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr. Blood Cancer 46, 579-585 (2006).
9. R. A. Van Etten, K. M. Shannon, Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6, 547-552 (2004).
10. B. S. Braun, D. A. Tuveson, N. Kong, D. T. Le, S. C. Kogan, J. Rozmus, M. M. Le Beau, T. E. Jacks, K. M. Shannon, Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl. Acad. Sci. U.S.A. 101, 597-602 (2004).
11. P. D. Emanuel, L. J. Bates, R. P. Castleberry, R. J. Gualtieri, K. S. Zuckerman, Selective hypersensitivity to granulocyte-macrophage colony stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77, 925-929 (1991).
12. I. T. Chan, J. L. Kutok, I. R. Williams, S. Cohen, L. Kelly, H. Shigematsu, L. Johnson, K. Akashi, D. A. Tuveson, T. Jacks, D. G. Gilliland, Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest. 113, 528-538 (2004).
13. C. Guerra, N. Mijimolle, A. Dhawahir, P. Dubus, M. Barradas, M. Serrano, V. Campuzano, M. Barbacid, Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111-120 (2003).
14. G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-387 (2004).
15. N. Lyubynska, M. F. Gorman, J. O. Lauchle, W. X. Hong, J. K. Akutagawa, K. Shannon, B. S. Braun, A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci. Transl. Med. 3, 76ra27 (2011).
16. Z. A. Knight, K. M. Shokat, Chemical genetics: Where genetics and pharmacology meet. Cell 128, 425-430 (2007).
17. R. A. Birnbaum, A. O'Marcaigh, Z. Wardak, Y. Y. Zhang, G. Dranoff, T. Jacks, D. W. Clapp, K. M. Shannon, Nf1 and Gmcsf interact in myeloid leukemogenesis. Mol. Cell 5, 189-195 (2000).
18. P. O. Iversen, I. D. Lewis, S. Turczynowicz, H. Hasle, C. Niemeyer, K. Schmiegelow, S. Bastiras, A. Biondi, T. P. Hughes, A. F. Lopez, Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood 90, 4910-4917 (1997).
19. A. Kim, K. Morgan, D. E. Hasz, S. M. Wiesner, J. O. Lauchle, J. L. Geurts, M. D. Diers, D. T. Le, S. C. Kogan, L. F. Parada, K. Shannon, D. A. Largaespada, b common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant mice. Blood 109, 1687-1691 (2007).
20. J. M. Irish, R. Hovland, P. O. Krutzik, O. D. Perez, Ø. Bruserud, B. T. Gjertsen, G. P. Nolan, Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118, 217-228 (2004).
21. G12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. Blood 109, 3945-3952 (2007).
22. C. J. Bagley, J. M. Woodcock, F. C. Stomski, A. F. Lopez, The structural and functional basis of cytokine receptor activation: Lessons from the common b subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 receptors. Blood 89, 1471-1482 (1997).
23. A. P. Brown, T. C. Carlson, C. M. Loi, M. J. Graziano, Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59, 671-679 (2007).
24. J. E. Bleasdale, N. R. Thakur, R. S. Gremban, G. L. Bundy, F. A. Fitzpatrick, R. J. Smith, S. Bunting, Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J. Pharmacol. Exp. Ther. 255, 756-768 (1990).
25. R. J. Smith, L. M. Sam, J. M. Justen, G. L. Bundy, G. A. Bala, J. E. Bleasdale, Receptor-coupled signal transduction in human polymorphonuclear neutrophils: Effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. J. Pharmacol. Exp. Ther. 253, 688-697 (1990).
26. Z. A. Knight, B. Gonzalez, M. E. Feldman, E. R. Zunder, D. D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Toth, T. Balla, W. A. Weiss, R. L. Williams, K. M. Shokat, A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell 125, 733-747 (2006).
27. B. F. Goemans, C. M. Zwaan, M. Miller, M. Zimmermann, A. Harlow, S. Meshinchi, A. H. Loonen, K. Hählen, D. Reinhardt, U. Creutzig, G. J. Kaspers, M. C. Heinrich, Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19, 1536-1542 (2005).
28. T. M. Kohl, S. Schnittger, J. W. Ellwart, W. Hiddemann, K. Spiekermann, KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor. Blood 105, 3319-3321 (2005).
29. R. J. Chan, M. B. Leedy, V. Munugalavadla, C. S. Voorhorst, Y. Li, M. Yu, R. Kapur, Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocytemacrophage colony-stimulating factor. Blood 105, 3737-3742 (2005).
30. S. Schubbert, K. Lieuw, S. L. Rowe, C.M. Lee, X. Li, M. L. Loh, D.W. Clapp, K.M. Shannon, Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. Blood 106, 311-317 (2005).
31. P. J. Cullen, P. J. Lockyer, Integration of calcium and Ras signalling. Nat. Rev. Mol. Cell Biol. 3, 339-348 (2002).
32. C. M. Leon, C. M. Barbosa, G. Z. Justo, P. Borelli, J. D. Resende Jr., J. S. de Oliveira, A. T. Ferreira, E. J. Paredes-Gamero, Requirement for PLCg2 in IL-3 and GM-CSFstimulated MEK/ERK phosphorylation in murine and human hematopoietic stem/progenitor cells. J. Cell. Physiol. 226, 1780-1792 (2011).
33. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P. N. Ibrahim, H. Cho, W. Spevak, C. Zhang, Y. Zhang, G. Habets, E. A. Burton, B. Wong, G. Tsang, B. L. West, B. Powell, R. Shellooe, A. Marimuthu, H. Nguyen, K. Y. Zhang, D. R. Artis, J. Schlessinger, F. Su, B. Higgins, R. Iyer, K. D'Andrea, A. Koehler, M. Stumm, P. S. Lin, R. J. Lee, J. Grippo, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. B. Chapman, K. T. Flaherty, X. Xu, K. L. Nathanson, K. Nolop, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
34. K. T. Flaherty, I. Puzanov, K. B. Kim, A. Ribas, G. A. McArthur, J. A. Sosman, P. J. O'Dwyer, R. J. Lee, J. F. Grippo, K. Nolop, P. B. Chapman, Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
35. G. Hatzivassiliou, K. Song, I. Yen, B. J. Brandhuber, D. J. Anderson, R. Alvarado, M. J. Ludlam, D. Stokoe, S. L. Gloor, G. Vigers, T. Morales, I. Aliagas, B. Liu, S. Sideris, K. P. Hoeflich, B. S. Jaiswal, S. Seshagiri, H. Koeppen, M. Belvin, L. S. Friedman, S. Malek, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
36. S. J. Heidorn, C.Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, N. Dhomen, J. Hussain, J. S. Reis-Filho, C. J. Springer, C. Pritchard, R. Marais, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
37. P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, N. Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
38. A. J. Sabnis, L. S. Cheung, M. Dail, H. C. Kang, M. Santaguida, M. L. Hermiston, E. Passegué, K. Shannon, B. S. Braun, Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLOS Biol. 7, e59 (2009).
39. J. Zhang, J. Wang, Y. Liu, H. Sidik, K. H. Young, H. F. Lodish, M. D. Fleming, Oncogenic Kras-induced leukemogeneis: Hematopoietic stem cells as the initial target and lineagespecific progenitors as the potential targets for final leukemic transformation. Blood 113, 1304-1314 (2009).
40. F. I. Raynaud, S. A. Eccles, S. Patel, S. Alix, G. Box, I. Chuckowree, A. Folkes, S. Gowan, A. De Haven Brandon, F. Di Stefano, A. Hayes, A. T. Henley, L. Lensun, G. Pergl-Wilson, A. Robson, N. Saghir, A. Zhyvoloup, E. McDonald, P. Sheldrake, S. Shuttleworth, M. Valenti, N. C.Wan, P. A. Clarke, P.Workman, Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: From PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 8, 1725-1738 (2009).
41. K. H. Lim, C. M. Counter, Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8, 381-392 (2005).
42. P. Rodriguez-Viciana,P. H.Warne, A. Khwaja, B. M. Marte, D. Pappin,P. Das, M. D.Waterfield, A. Ridley, J. Downward, Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89, 457-467 (1997).
43. M. A. White, C. Nicolette, A. Minden, A. Polverino, L. Van Aelst, M. Karin, M. H. Wigler, Multiple Ras functions can contribute to mammalian cell transformation. Cell 80, 533-541 (1995).
44. J. A. Engelman, L. Chen, X. Tan, K. Crosby, A. R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S. A. Perera, Y. Song, L. R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R. F. Padera, C. García- Echeverría, R. Weissleder, U. Mahmood, L. C. Cantley, K. K. Wong, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
45. S. Gupta, A. R. Ramjaun, P. Haiko, Y. Wang, P. H. Warne, B. Nicke, E. Nye, G. Stamp, K. Alitalo, J. Downward, Binding of ras to phosphoinositide 3-kinase p110a is required for ras-driven tumorigenesis in mice. Cell 129, 957-968 (2007).
46. B. C. Duckworth, L. C. Cantley, Conditional inhibition of the mitogen-activated protein kinase cascade by wortmannin. Dependence on signal strength. J. Biol. Chem. 272, 27665-27670 (1997).
47. Q. Hu, A. Klippel, A. J. Muslin, W. J. Fantl, L. T. Williams, Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 268, 100-102 (1995).
48. I. Rubio, R. Wetzker, A permissive function of phosphoinositide 3-kinase in Ras activation mediated by inhibition of GTPase-activating proteins. Curr. Biol. 10, 1225-1228 (2000).
49. C. Sampaio, M. Dance, A. Montagner, T. Edouard, N. Malet, B. Perret, A. Yart, J. P. Salles, P. Raynal, Signal strength dictates phosphoinositide 3-kinase contribution to Ras/extracellular signal-regulated kinase 1 and 2 activation via differential Gab1/Shp2 recruitment: Consequences for resistance to epidermal growth factor receptor inhibition. Mol. Cell. Biol. 28, 587-600 (2008).
50. S. Wennström, J. Downward, Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell. Biol. 19, 4279-4288 (1999).
51. C. Hartzell, O. Ksionda, E. Lemmens, K. Coakley, M. Yang, M. Dail, R. C. Harvey, C. Govern, J. Bakker, T. L. Lenstra, K. Ammon, A. Boeter, S. S.Winter, M. Loh, K. Shannon, A. K. Chakraborty, M. Wabl, J. P. Roose, Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis. Sci. Signal. 6, ra21 (2013).
52. 2 lipids target proteins with polybasic clusters to the plasma membrane. Science 314, 1458- 1461 (2006).
53. S. J. Plowman, C. Muncke, R. G. Parton, J. F. Hancock, H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. Proc. Natl. Acad. Sci. U.S.A. 102, 15500-15505 (2005).
54. T. Tian, A. Harding, K. Inder, S. Plowman, R. G. Parton, J. F. Hancock, Plasma membrane nanoswitches generate high-fidelity Ras signal transduction. Nat. Cell Biol. 9, 905-914 (2007).
55. G. W. Reuther, Q. T. Lambert, J. F. Rebhun, M. A. Caligiuri, L. A. Quilliam, C. J. Der, RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. J. Biol. Chem. 277, 30508-30514 (2002).
56. T. G. Bivona, I. Pérez De Castro, I. M. Ahearn, T. M. Grana, V. K. Chiu, P. J. Lockyer, P. J. Cullen, A. Pellicer, A. D. Cox, M. R. Philips, Phospholipase Cg activates Ras on the Golgi apparatus by means of RasGRP1. Nature 424, 694-698 (2003).
57. C. Fellmann, J. Zuber, K. McJunkin, K. Chang, C. D. Malone, R. A. Dickins, Q. Xu, M. O. Hengartner, S. J. Elledge, G. J. Hannon, S. W. Lowe, Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol. Cell 41, 733-746 (2011).
58. E. L. Jackson, N. Willis, K. Mercer, R. T. Bronson, D. Crowley, R. Montoya, T. Jacks, D. A. Tuveson, Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
59. S. Schubbert, M. Zenker, S. L. Rowe, S. Böll, C. Klein, G. Bollag, I. van der Burgt, L. Musante, V. Kalscheuer, L. E.Wehner, H. Nguyen, B. West, K. Y. Zhang, E. Sistermans, A. Rauch, C. M. Niemeyer, K. Shannon, C. P. Kratz, Germline KRAS mutations cause Noonan syndrome. Nat. Genet. 38, 331-336 (2006).
60. S. Donovan, W. See, J. Bonifas, D. Stokoe, K. M. Shannon, Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. Cancer Cell 2, 507-514 (2002).
61. J. Zuber, J. Shi, E. Wang, A. R. Rappaport, H. Herrmann, E. A. Sison, D. Magoon, J. Qi, K. Blatt, M.Wunderlich, M. J. Taylor, C. Johns, A. Chicas, J. C. Mulloy, S. C. Kogan, P. Brown, P. Valent, J. E. Bradner, S.W. Lowe, C. R. Vakoc, RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).